ASCO 2026: Monjuvi to rival Polivy in 1L DLBCL after strong Phase III results

Incyte's Monjuvi Shows Strong Phase III PFS in First-Line DLBCL

Incyte announced positive Phase III results for its CD19 monoclonal antibody, tafasitamab (Monjuvi/Minjuvi), in combination with lenalidomide and R-CHOP (Tafa-Len-R-CHOP) for newly diagnosed, untreated diffuse large B-cell lymphoma (DLBCL) patients. Presented at the American Society for Clinical Oncology (ASCO) Annual Meeting in May 2026, the frontMIND trial (NCT04824092) demonstrated a statistically significant improvement in progression-free survival (PFS) compared to R-CHOP alone, with a two-year PFS of 71.1% versus 62.9% (HR 0.75; p=0.019). While efficacy was promising, the combination did lead to a higher incidence of grade 3 or higher treatment-emergent adverse events. Incyte plans to submit a supplemental Biologics License Application (sBLA) based on these findings.

• The frontMIND trial demonstrated a statistically significant improvement in progression-free survival (PFS) for Tafa-Len-R-CHOP over R-CHOP alone, with a hazard ratio of 0.75 (95% CI: 0.59, 0.96) and a p-value of 0.019. This translated to an 8.2% improvement in two-year PFS (71.1% vs 62.9%), indicating a meaningful clinical benefit for newly diagnosed DLBCL patients after a median follow-up of 35.2 months.
• While effective, the Tafa-Len-R-CHOP regimen was associated with a higher incidence of grade 3 or higher treatment-emergent adverse events (86.7% vs 76.1% for R-CHOP), including more serious febrile neutropenia (13.3% vs 9.8%). There were also higher rates of TEAE-dependent discontinuation (25.7% vs 17.9%) and TEAE-related deaths (5.9% vs 3.8%). Despite these, side effects were generally considered clinically manageable.
• Monjuvi's positive results, particularly its consistent efficacy across both germinal centre B-cell (GCB) and activated B-cell (ABC) molecular subtypes of DLBCL, position it as a strong competitor to Roche's Polivy (polatuzumab vedotin) in the first-line setting. Polivy's R-CHP combination, while approved, does not show clinically meaningful improvement in GCB DLBCL patients, offering Monjuvi a potential advantage in this large patient group. GlobalData forecasts Monjuvi to approach $2 billion in global annual sales by 2032.

Addressing the Gaps in First-Line DLBCL Treatment

Current DLBCL treatment approaches face significant challenges that limit therapeutic success and patient outcomes. Despite R-CHOP remaining the standard first-line therapy, substantial gaps persist in achieving durable responses across all patient populations. These limitations underscore the urgent need for innovative treatment strategies and better patient selection approaches.

• High relapse and treatment failure rates: 30-40% of patients treated with first-line R-CHOP chemoimmunotherapy experience relapse, with 10% showing primary refractory disease, and up to 50% of patients eligible for second-line salvage therapy followed by autologous stem-cell transplantation subsequently experience relapse

• Poor outcomes in relapsed/refractory settings: Patients with advanced relapsed/refractory disease have a median overall survival of only 6-12 months, with Medicare beneficiaries showing a median survival of just 6.7 months from second-line therapy initiation, and only 30.6% of patients proceeding to third-line treatment

• Limited efficacy of frontline therapy enhancements: Attempts to improve outcomes by adding targeted agents to the R-CHOP backbone have consistently failed to demonstrate expected benefits, with none of the numerous targeted and immunological therapies successfully enhancing frontline therapy efficacy

• Disease heterogeneity challenges: DLBCL's genetically heterogeneous nature creates significant treatment complexity, with specific subtypes like CD5-positive DLBCL showing worse outcomes due to inherent chemotherapy resistance and more aggressive clinical behavior

• Treatment-related toxicity and complications: CAR T-cell therapy, while promising, carries substantial risks with 99-100% of patients experiencing adverse events of any grade, 68-98% experiencing grade ≥3 events, and cytokine release syndrome occurring in 42-100% of participants, requiring specialized management expertise

• Transplantation limitations: Autologous stem cell transplantation effectiveness is restricted to chemosensitive patients, while allogeneic transplantation benefits are often limited by treatment-related mortality from graft-versus-host disease, preparative regimen toxicity, and compromised immune recovery

Unpacking frontMIND: Tafasitamab's Efficacy and Safety Profile

Recent clinical trials in diffuse large B-cell lymphoma (DLBCL) have employed diverse study designs to evaluate both established and novel therapeutic approaches across different treatment lines. These studies range from large-scale phase III randomized controlled trials to real-world evidence studies, incorporating both prospective and retrospective methodologies to comprehensively assess treatment efficacy and safety.

Tafasitamab's Differentiated Role in the 1L DLBCL Landscape

Recent investigational therapies for DLBCL demonstrate varying degrees of improvement over standard-of-care R-CHOP, with the most promising results observed in molecularly-defined patient populations. BTK inhibitors combined with R-CHOP show particularly compelling outcomes for patients with MYD88 and/or CD79B mutations, achieving 100% overall response rates and 94.4% complete response rates compared to 70.6% ORR and 52.9% CRR with R-CHOP alone. Similarly, polatuzumab vedotin-based combinations have shown enhanced efficacy, with polatuzumab vedotin plus zanubrutinib achieving 70% overall response rates and 45% complete response rates in relapsed/refractory settings, while polatuzumab vedotin-R-CHP demonstrated superior progression-free survival compared to standard R-CHOP in intermediate- and intermediate-high-risk patients.

CD20-directed bispecific antibodies represent another significant advancement, with epcoritamab and glofitamab achieving overall response rates of 51% and 53% respectively in heavily pretreated relapsed/refractory DLBCL patients. Glofitamab specifically demonstrated a 65.7% ORR with 57.1% complete responses at the recommended phase II dose, with 84.1% of complete responders maintaining ongoing responses. These agents offer meaningful alternatives for patients who have exhausted traditional therapies, though cytokine release syndrome remains a manageable but notable adverse event occurring in approximately 50% of patients.

Standard R-CHOP continues to serve as the backbone therapy for newly diagnosed DLBCL, with real-world outcomes demonstrating 3-year overall survival rates ranging from 51-87% depending on risk stratification. However, recent data suggest that risk-adapted approaches incorporating novel agents may improve outcomes for specific patient subsets. Tafasitamab plus lenalidomide has shown particular promise in the relapsed/refractory setting, achieving 51% overall response rates with a median overall survival of 12.2 months in intention-to-treat populations, positioning it as a viable option within the evolving treatment landscape for patients who cannot receive intensive chemotherapy regimens.

Tafasitamab's Front-Line Breakthrough: Reshaping Newly Diagnosed DLBCL

For decades, R-CHOP has stood as the bedrock of first-line therapy for diffuse large B-cell lymphoma (DLBCL), a regimen that, while effective for many, still leaves a significant proportion of patients facing relapse or refractory disease. The recent announcement of positive Phase III frontMIND results for tafasitamab in combination with lenalidomide and R-CHOP (Tafa-Len-R-CHOP) marks a potentially transformative moment, signaling a new era for newly diagnosed DLBCL treatment.

The statistically significant improvement in progression-free survival (PFS) demonstrated by Tafa-Len-R-CHOP over R-CHOP alone is a compelling clinical advance. This data suggests that incorporating tafasitamab, an anti-CD19 monoclonal antibody already established in the relapsed/refractory setting, into the initial treatment paradigm could offer patients a more durable response. This strategic move into the upfront setting represents a substantial expansion of tafasitamab's market potential, positioning it to redefine the standard of care and intensify competition among therapies aiming to improve upon R-CHOP.

However, this promising efficacy comes with important considerations. The trial reported a higher incidence of grade 3 or higher treatment-emergent adverse events with the combination. This increased toxicity profile will be a critical factor for clinicians, who must carefully weigh the benefits of improved PFS against potential side effects, especially in a first-line population generally expected to tolerate therapy well. Successful integration into clinical practice will depend on robust patient selection strategies and proactive management of adverse events.

• Clinical Impact: The data offers a new, more effective first-line option, potentially improving long-term outcomes for a broader range of DLBCL patients.

• Market Dynamics: This development could shift market leadership in newly diagnosed DLBCL, prompting competitors to accelerate their own first-line development programs.

• Patient Management: The increased toxicity necessitates careful patient counseling and proactive supportive care to ensure the benefits are realized safely.

Ultimately, while the path to widespread adoption will involve navigating regulatory reviews and clinical integration challenges, the frontMIND results underscore a significant step forward in the fight against DLBCL, offering renewed hope for patients and a dynamic shift for the pharmaceutical landscape.